Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Susan Young Rojahn

A View from Susan Young Rojahn

Outlier Patients in Cancer Drug Trials Could Personalize Treatment

Researchers use DNA sequencing to identify the molecular basis of a patient’s unique but beneficial response to an experimental cancer drug.

  • August 23, 2012

No cancer is like any other, so it’s no surprise that there’s a lot of variability in how patients respond to cancer drugs. This variability creates a challenge for drug developers: A  compound can fail in clinical trials if it does not reverse or at least stall disease progression in a significant percentage of patients, even if it greatly helps some.

Researchers at Memorial Sloan-Kettering Cancer Center in New York examined one such case in a clinical trial of a drug called everolimus. While most patients in the trial were not helped by the drug, one did experience a remarkable recovery. The metastatic bladder cancer of this patient disappeared after a few months on everolimus.

By comparing the genome of this patient’s cancer to his or her healthy genome, the researchers identified a mutation in a gene known to be linked to everolimus’ molecular target. They then looked for mutations in the same gene in 13 other patients involved in the trial. Of the four additional patients with mutations in that gene, three had shown minor positive responses to everolimus, the team reports today in Science.

The authors write that the results show that tumor genome sequencing can identify previously unrecognized biomarkers for drug response in solid tumors. They also suggest that the genomes of tumors from “outlier” patients, who respond to a drug when many others don’t, may provide clues for identifying other patients who could also be helped by the treatment

“Although single patient anecdotes are often dismissed as failing to provide meaningful clinical evidence, this example illustrates the potential for such cases to inform future clinical development of drugs in molecularly defined populations.”

Cut off? Read unlimited articles today.

Become an Insider
Already an Insider? Log in.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.